Poster

Developing A High-Throughput Formulation Development Platform For High-Concentration, Therapeutic Monoclonal Antibodies

Source: Catalent

By Jessica Ripley, Shyamal Choudhari, Lun Xin, Spencer Beard, Victor Vinci, and Yunsong Li

Some of the challenges in the early stages of a pharmaceutical are a limited supply of protein to use in formulation screening studies, and a need to obtain stability data quickly to initiate tox studies. One approach commonly used to conserve protein is to screen a large number of excipients at a lower concentration and then use the data generated to predict high-concentration trends.

However, trends observed at low protein concentration may not reflect the trends at a higher concentration where long-term stability is more likely to be a concern. This work demonstrates how a high-throughput, micro-well plate platform can be used to economically screen a model IgG1 mAb at 120 mg/ml in 96 formulations while minimizing protein consumed and generating large amount of data quickly. To evaluate the risk of using low-concentration data to predict stability trending at higher concentrations comparisons are made between the screening study executed at a high (120mg/mL) vs. low ( < 10 mg/mL) mAb concentration.

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: